NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Crescent Biopharma, Inc. CBIO
14 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$10.8M
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-164.2%
Net margin · FY25
-1419.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 10.8M
Revenue, FY2025 · full 14-year series below
Revenue
Net income
The company lost 1420 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-164.2%
Return on equity, FY2025
ROE
Operating margin-1407.5%
Net margin-1419.6%
Return on assets-111.6%
Each USD of equity lost 164 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+1.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+424.9%
+1.3%
−6.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2025
Change, 5 years+49.2%
Change, 10 years—
The share count grew 49% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 240.3M
total assets, end of FY2025
Total assetsUSD 240.3M
EquityUSD 203.0M
CashUSD 213.2M
Current ratio6.56×
Equity funds 84% of total assets.
History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Revenue $B
0.0
·
0.0
0.0
0.0
0.0
·
·
·
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.2
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
EBITDA $B
−0.2
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
Income tax $B
0.0
·
·
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.2
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
EPS, diluted $
·
−0.59
−0.58
−0.89
−1.23
−1.12
−1.34
−1.18
−1.13
−1.50
−0.67
−0.60
−8.87
0.33
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−164.2
−330.3
−90.7
−75.0
−60.5
−36.1
−32.2
−29.7
−42.9
−84.0
−28.0
−41.4
−137.4
29.2
Shares out B
0.03
0.00
0.06
0.05
0.05
0.05
0.04
0.04
0.03
0.02
0.02
0.02
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
39 of 39
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed